![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 27, 2013 10:11:48 AM
The process has been a bit longer than expected but in the long run, over-coming a substantial barrier to entry serves to protect our proprietary formulations in the nausea relief product against competitors' attempts at any improper replications," says Dr. Charles Hensley. "An extremely important key to this product is not only its efficacy but also having the product and its active blends be difficult for competitors to duplicate. By working closely with the manufacturer, we have been able to accomplish this by using a dedicated Rotavap, which has allowed us to scale up our bench formula while keeping the usually water insoluble actives in solution in a way that does not create discomfort in the consumer's the nasal passage."
I suppose they want it difficult, but perhaps not impossible to duplicate. By the same token, it would not only be the Chinese trying but anybody else with the means also, even in the USA or Europe.
Are we rich yet?
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM